**Author details**

Ota Fuchs Institute of Hematology and Blood Transfusion, Prague, Czech Republic

\*Address all correspondence to: ota.fuchs@uhkt.cz

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**5**

*Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment…*

[8] Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Seminars in Cancer Biology. 2014; **27**: 52-61. DOI: 10.1016/

[9] Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden KLB. A biochemical framework for eIF4Edependent mRNA export and nuclear recycling of the export machinery. RNA. 2017; **23**(6): 927-937. DOI: 10.1261/

[10] Schmidt J, Braggio E, Kortuem KM,

Egan JB, Zhu YX, Xin CS, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013; **27**(12): 2357-2365.

DOI: 10.1038/leu.2013.172

Mohammad RM. Nuclear export

inhibition for pancreatic cancer therapy. Cancers (Basel). 2018; **10**(5): 138. DOI:

[13] Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discovery. 2019; **9**(10): 1452-1467. DOI: 10.1158/2159-8290.

[14] Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, et al. Leptomycin B inhibition of signalmediated nuclear export by direct

[11] Muqbil I, Azmi AS,

103390/cancers10050138

prot.2019.103504

CD-19-0298

[12] Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Kumar S, et al. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. Journal of Proteomics. 2019; **209**: 103504. DOI: 10.1016/j.

semcancer.2014.03.002

rna.060137.116

*DOI: http://dx.doi.org/10.5772/intechopen.96945*

[2] Nguen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. International Journal of Biochemistry and Molecular Biology. 2012; **3**(2): 137- 151. PMID: 22773955/ISSN: 2152-4114/

[3] Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Seminars in Cance Biology. 2014; **27**: 62-73. DOI: 10.1016/j.

[4] Gravina GL, Senapedis W, Mc Cauley D, Baloglu E, Shacham S,

Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. Journal of Hematology & Oncology. 2014; **7**: 85. DOI: 10.1186/s13045-014-0085-1

[5] Lu C, Figueroa JA, Liu Z, Konala V, Aulakh A, Verma R, et al. Nuclear export as a novel therapeutic target: the CRM1 connection. Current Cancer Drug Targets. 2015; **15**(7): 575-592. DOI: 10.2174/15680096150715

[6] Monecke T, Güttler T, Neumann P, Dickmanns A, Görlich D, Ficner R. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science. 2009; **324**(5930): 1087-1091. DOI:

[7] Monecke T, Dickmanns A, Ficner R. Allosteric control of the exportin CRM1 unraveled by crystal structure analysis. FEBS Journal. 2014; **281**(18): 4179-4194.

10.1126/science.1173388

DOI: 10.1111/febs.12842

IJBM 1204001

**References**

semcancer.2014.03.001

0828223554

[1] Turner JG, Sullivan DM. CRM1 mediated nuclear export of proteins and drug resistance in cancer. Current Medicinal Chemistry. 2008; **15**(26): 2648-2655. DOI: 10.2174/092986708786242859

*Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment… DOI: http://dx.doi.org/10.5772/intechopen.96945*
